60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report)‘s stock had its “neutral” rating reiterated by HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports.
60 Degrees Pharmaceuticals Price Performance
NASDAQ:SXTP traded up $0.40 during trading hours on Wednesday, hitting $2.35. 2,767,188 shares of the company were exchanged, compared to its average volume of 277,863. The stock has a market capitalization of $5.40 million, a price-to-earnings ratio of -0.23 and a beta of 5.36. 60 Degrees Pharmaceuticals has a 52-week low of $0.70 and a 52-week high of $18.36. The company’s 50 day moving average price is $1.01 and its 200-day moving average price is $0.83.
Insiders Place Their Bets
In other 60 Degrees Pharmaceuticals news, CEO Geoffrey S. Dow acquired 35,823 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were acquired at an average cost of $1.27 per share, with a total value of $45,495.21. Following the acquisition, the chief executive officer now directly owns 94,580 shares of the company’s stock, valued at approximately $120,116.60. The trade was a 60.97 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. In the last quarter, insiders have purchased 59,372 shares of company stock valued at $70,410. Insiders own 10.27% of the company’s stock.
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.
See Also
- Five stocks we like better than 60 Degrees Pharmaceuticals
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- The Great CPU Race: AMD and Intel Battle for Dominance
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- GameStop Turns a Profit: So What? It’s Still Not Worth Investing
- Insider Buying Explained: What Investors Need to Know
- C3.ai Stock Surges on Strong Sales Despite Profit Concerns
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
